CSRM617 is a potent and selective inhibitor of PRMT5 (protein arginine methyltransferase 5), primarily utilized in the field of oncology research to investigate its role in cancer cell proliferation and survival. It targets aberrant protein methylation pathways that drive tumor growth, serving as a valuable tool compound for developing targeted cancer therapies. Researchers employ CSRM617 in preclinical studies to assess its efficacy in inhibiting tumor progression and to elucidate its molecular mechanism of action. Additionally, it is used in combination with other anticancer agents to explore potential synergistic effects and improve therapeutic outcomes. Its application is particularly relevant for studying cancers resistant to conventional therapies.